Mitochondrial Replacement (Public Safety)

Mary Glindon Excerpts

Monday 1st September 2014 Commons Chamber

[Mrs Mary Glindon (North Tyneside) (Lab)]

I congratulate the hon. Member for Congleton (Fiona Bruce) on securing the debate.

Members may not have heard of ovarian hyper-stimulation syndrome, or OHSS, as it receives little coverage in the media, but it is one of the most serious complications associated with the use of certain fertility drugs during the procedure known as controlled ovarian hyper-stimulation, which is a part of fertility treatment used to ensure that the number of eggs collected is as high as possible. OHSS is not uncommon—research suggests that as many as a third of women who undergo controlled hyper-stimulation experience some symptoms, although serious cases are relatively rare. Younger women, women with certain pre-existing health problems such as polycystic ovaries, and women who have had OHSS before, are particularly at risk. Severe cases of OHSS can be very dangerous and even life-threatening, with painful and debilitating symptoms. However, monitoring of cases of OHSS is far from adequate. In answer to a parliamentary question, the Under-Secretary of State for Health, the hon. Member for Battersea (Jane Ellison), stated that

“The HFEA does not…hold definitive data on the number of women admitted to hospital with OHSS, including non-patient egg donors and egg-share donors.”—[Official Report, 9 July 2014; Vol. 584, c. 313W.]

[Mr Jim Cunningham (Coventry South) (Lab)]

Does my hon. Friend agree that it is probably necessary for the Government to bring proposals to the House for us to consider? There is not a lot of understanding about the disease outside the House and the public could be better informed, whichever way the decision goes.

[Mrs Glindon]

I agree. There is probably not enough understanding within the House, either.

The Minister had previously said:

“licensed fertility clinics are only required to report instances of OHSS to the authority that require a hospital admission with a severe grading, although in practice clinics often report moderate OHSS as well.”—[Official Report, 24 June 2014; Vol. 583, c. 157W.]

The figures that do exist indicate there has been a small recent increase both in the total number of recorded cases and in those cases categorised as “severe” rather than “moderate”. About 50,000 women go through IVF in the UK each year. The fact that we do not collect proper data on a potentially life-threatening condition that may affect a third of them, seems an astonishing oversight in the collection of official health statistics. Mandatory reporting of all cases is an essential first step in this process, but should only be the start of more effective and careful collection of statistics.

This issue has a particular pertinence at present because of proposed changes to the law on mitochondrial transfer and the Government’s stated intention to allow the creation of three-parent embryos. I am sure that many Members may be struggling to get to grips with the details of this procedure, but simply put both of the techniques used in mitochondrial transfer require a significant supply of donor eggs. Any such eggs will have to come from women who have been through controlled ovarian hyper-stimulation, with all the attendant risks.

[Martin Horwood (Cheltenham) (LD)]

Will the hon. Lady give way?

[Mrs Glindon]

I will not. Sorry. There is not time.

It appears that very little consideration has been given to this fact in any of the various consultations and Government position papers that have emerged over the past two or three years. No in-depth questions about the physical health of women donating eggs were addressed in the HFEA’s own briefings. Will the Minister assure the House that she will take the matter back to her Department for consideration? In the light of the safety concerns we have heard today associated with the proposed techniques, such action would appear to be urgent, for the sake of the vulnerable women involved.